Brokerages Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Target Price at $7.25

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been assigned an average rating of “Hold” from the six analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $7.25.

Several analysts recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Saturday, September 27th. Finally, Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 target price for the company.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.52, for a total transaction of $202,026.48. Following the transaction, the insider owned 668,197 shares in the company, valued at $3,688,447.44. This represents a 5.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.43% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. TD Waterhouse Canada Inc. grew its position in Recursion Pharmaceuticals by 64.1% during the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock worth $29,000 after buying an additional 2,200 shares in the last quarter. AlphaQuest LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth $36,000. GAMMA Investing LLC grew its holdings in shares of Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after purchasing an additional 2,026 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Recursion Pharmaceuticals by 97.2% in the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock worth $46,000 after purchasing an additional 4,446 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new position in Recursion Pharmaceuticals in the second quarter valued at about $51,000. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Stock Down 0.5%

Shares of RXRX opened at $5.49 on Friday. The firm has a market cap of $2.38 billion, a P/E ratio of -3.08 and a beta of 0.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.58 and a current ratio of 3.58. Recursion Pharmaceuticals has a 52 week low of $3.79 and a 52 week high of $12.36. The firm’s 50-day simple moving average is $5.10 and its 200 day simple moving average is $5.13.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The company had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. During the same period in the prior year, the company earned ($0.40) earnings per share. The firm’s revenue was up 33.3% compared to the same quarter last year. On average, analysts forecast that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.